Login Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

  • Watchlist

    Keep track of companies that you follow and research.

  • 10 Years of Data

    Full access to our data with predictions and indicators that we calculate daily.

  • Screener

    Full access to our screener with tons of custom values and customizable email notifications.

  • XLS Exports

    Excel export of financials and screeners you define and save.

Subscribe now
Screener Weekly Summary

Bio-Rad Laboratories, Inc. BIO

Healthcare  —  Medical Devices
Cash Flow Champion (3y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Analyst Commentary Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Bio-Rad Laboratories, Inc. (BIO) Business Profile

Company Overview

Bio-Rad Laboratories, Inc. (BIO) is a global leader in the development, manufacturing, and marketing of innovative products for the life sciences research and clinical diagnostics markets. Founded in 1952 by David and Alice Schwartz, the company is headquartered in Hercules, California, USA. Over the decades, Bio-Rad has grown into a multinational corporation with a presence in over 35 countries, employing thousands of professionals worldwide. The company is publicly traded on the New York Stock Exchange under the ticker symbol “BIO.”

Bio-Rad’s leadership team is composed of experienced professionals who drive the company’s strategic vision. Norman Schwartz, the son of the founders, serves as the Chairman of the Board and has played a pivotal role in the company’s growth. The executive team includes Ilan Daskal as Chief Financial Officer and Andrew Last as Chief Operating Officer, among others. Their collective expertise ensures that Bio-Rad remains at the forefront of innovation and operational excellence.

Core Business Segments

Bio-Rad operates through two primary business segments: Life Science and Clinical Diagnostics. Each segment offers a diverse range of products and services tailored to meet the needs of its customers.

Life Science Segment

The Life Science segment focuses on providing tools and technologies for researchers in academia, biotechnology, and pharmaceutical industries. Key product categories include:

  • Gene Expression and Genomics: Bio-Rad offers real-time PCR systems, digital PCR systems, and reagents that enable precise gene expression analysis and genomic studies.
  • Protein Analysis: The company provides electrophoresis systems, western blotting instruments, and reagents for protein separation and analysis.
  • Cell Biology: Bio-Rad’s cell imaging systems and flow cytometers are widely used in cell biology research.
  • Bioprocessing: The company offers chromatography systems and resins for large-scale protein purification and biopharmaceutical production.

Clinical Diagnostics Segment

The Clinical Diagnostics segment serves hospitals, reference laboratories, and other healthcare providers. Key product categories include:

  • Quality Control Systems: Bio-Rad is a market leader in quality control products for clinical laboratories, ensuring the accuracy and reliability of diagnostic tests.
  • Immunohematology: The company provides blood typing and screening products for transfusion medicine.
  • Diabetes Monitoring: Bio-Rad offers HbA1c testing systems for diabetes management.
  • Infectious Disease Testing: The company develops assays for detecting infectious diseases, including HIV and hepatitis.

Business Model

Bio-Rad’s business model is centered around innovation, customer-centric solutions, and a diversified product portfolio. The company integrates its products and services to provide end-to-end solutions for its customers. Revenue is generated through the sale of instruments, consumables, and services. Consumables, such as reagents and test kits, provide a recurring revenue stream, while service contracts and software solutions add additional value.

The company invests heavily in research and development (R&D) to maintain its competitive edge. By collaborating with academic institutions, industry partners, and customers, Bio-Rad ensures that its products address emerging scientific and clinical needs.

Strategic Direction

Bio-Rad is committed to driving growth through innovation, geographic expansion, and operational efficiency. Key strategic priorities include:

  • Product Innovation: The company plans to launch new products and enhance existing ones to meet evolving customer demands.
  • Geographic Expansion: Bio-Rad aims to strengthen its presence in emerging markets, particularly in Asia-Pacific and Latin America.
  • Sustainability Goals: The company is focused on reducing its environmental footprint by adopting sustainable manufacturing practices and promoting energy efficiency.
  • Digital Transformation: Bio-Rad is leveraging digital technologies to improve customer experiences and streamline operations.

Competitive Landscape

Bio-Rad operates in highly competitive markets, facing competition from both established players and emerging companies. Key competitors include:

  • Life Sciences: Thermo Fisher Scientific, Agilent Technologies, and Illumina.
  • Clinical Diagnostics: Roche Diagnostics, Abbott Laboratories, and Siemens Healthineers.

Despite the competition, Bio-Rad differentiates itself through its innovative products, strong brand reputation, and customer-focused approach.

Risk Factors

Bio-Rad faces several risks that could impact its business operations and financial performance. These include:

  • Market Dependence: The company’s revenue is heavily reliant on the life sciences and clinical diagnostics markets, which are subject to economic and regulatory fluctuations.
  • Supply Chain Disruptions: Global supply chain challenges, including shortages of raw materials and transportation delays, could affect product availability.
  • Regulatory Compliance: Bio-Rad operates in highly regulated industries and must comply with stringent standards, which can be costly and time-consuming.
  • Currency Fluctuations: As a global company, Bio-Rad is exposed to currency exchange rate risks.

Recent Developments

Bio-Rad has made significant strides in recent years, including:

  • Product Launches: The company introduced new digital PCR systems and advanced diagnostic assays to enhance its product portfolio.
  • Acquisitions: Bio-Rad acquired several companies to expand its capabilities in genomics and diagnostics.
  • COVID-19 Response: The company played a critical role in the global fight against COVID-19 by developing testing solutions and supporting vaccine research.

Investment Considerations

Investors considering Bio-Rad should weigh the following factors:

Strengths

  • Strong brand reputation and market leadership.
  • Diversified product portfolio with recurring revenue streams.
  • Commitment to innovation and R&D.
  • Global presence and geographic diversification.

Risks

  • Dependence on specific markets and products.
  • Exposure to regulatory and compliance risks.
  • Vulnerability to supply chain disruptions.

Conclusion

Bio-Rad Laboratories, Inc. is a well-established leader in the life sciences and clinical diagnostics markets. With a strong focus on innovation, customer satisfaction, and sustainability, the company is well-positioned for future growth. While it faces challenges such as market dependence and regulatory compliance, its strengths far outweigh the risks, making it an attractive option for investors and customers alike.